Histologically confirmed non-small cell lung cancer (NSCLC).
ALK-positive or ROS1-positive NSCLC in Stage IB-IIIA (according to the 8th American Joint Committee on Cancer TNM edition), as assessed by investigator.
Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a MDT evaluation (which should include a thoracic surgeon, specialized in oncologic procedures).
ECOG Performance Status of 0-1.
At least one measurable lesion according to RECIST 1.1.
Adequate organ and marrow function.
You may not be if
Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug.
Prior treatment with ALK TKI or ROS1 TKI.
Prior treatment with local radiotherapy.
Mixed small cell and NSCLC histology.
Patients who are candidates to undergo only segmentectomies or wedge resections.
